Everforth Inc quarterly report, Q2 FY2006

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: A diversified professional staffing firm operating in two segments: Lab Support (life sciences) and Healthcare Staffing (Nurse Travel and Medical Financial & Allied). The company provides contract professionals, contract-to-permanent placements, and direct hires.

Key Financial Metrics

Metric Three Months Ended
June 30, 2006
Six Months Ended
June 30, 2006
Revenues $68,636,000 $135,359,000
Gross Profit $19,268,000 $36,252,000
Gross Margin 28.1% 26.8%
Operating Income $2,624,000 $2,822,000
Net Income $1,914,000 $2,216,000
Diluted EPS $0.07 $0.08
Cash & Equivalents $28,611,000 $28,611,000 (Balance Sheet)
Restricted Cash $5,178,000 $5,178,000 (Balance Sheet)
Working Capital $53,630,000 $53,630,000
Total Debt $0 $0

Note: The company has no long-term debt or borrowing facilities in place as of June 30, 2006.

Material Changes vs. Prior Period

  • Revenue Growth: Revenues increased 19.6% year-over-year (Q2 2006 vs. Q2 2005) and 26.3% for the six-month period. Growth was driven by a 15.8% increase in the average number of contract professionals and a 3.2% increase in average bill rates.
  • Profitability Turnaround: The company returned to profitability, reporting Net Income of $1.9 million for the quarter compared to a Net Income of $146,000 in the prior year quarter. For the six months, the company reported a Net Income of $2.2 million compared to a Net Loss of $2.7 million in the prior year.
  • Segment Performance:
    • Lab Support: Revenues up 21.5% YoY; Gross margin improved 180 basis points to 33.4%.
    • Healthcare Staffing: Revenues up 18.2% YoY. MF&A revenues grew 34.2%, while Nurse Travel grew 12.0%.
  • Stock-Based Compensation: Adoption of FAS 123(R) resulted in a $555,000 expense for the quarter and $1.014 million for the six months, which was not present in the prior year comparables.

Guidance, Outlook, and Risks

  • Outlook: Management expects continued year-over-year revenue growth in Q3 2006, assuming stable labor markets and no loss of major Nurse Travel clients. The company is focusing on expanding Health Information Management (HIM), Local Nursing, Engineering, and Clinical Research lines.
  • Capital Expenditures: The company expects to incur approximately $3.5 million to $4.0 million in capital expenditures for 2006, primarily for PeopleSoft and Recruitmax software initiatives. $2.254 million has already been incurred for the six months ended June 30, 2006.
  • Liquidity: Working capital is strong at $53.6 million. Operating cash flows are the primary source of liquidity. The company has restricted cash of $5.178 million collateralizing letters of credit for workers' compensation.
  • Risks & Contingencies:
    • Valuation Allowance: The company maintains a valuation allowance against net deferred income tax assets due to prior years' losses, though it projects a 30% effective tax rate for 2006 based on expected utilization of net operating loss carryforwards.
    • Workers' Compensation: The company is partially self-insured. Liability is estimated based on historical experience; changes in trends could materially impact results.
    • Seasonality: Demand is historically lower in Q1 and Q4 due to holidays and client shutdowns.

Investor Verification Checklist

  • Revenue Quality: Verify the sustainability of the 19.6% revenue growth and the mix shift toward higher-margin Lab Support and MF&A segments.
  • Stock-Based Compensation Impact: Assess the ongoing impact of FAS 123(R) adoption on future operating margins, noting $2.7 million in unrecognized stock option expense and $4.1 million in RSU expense remaining.
  • Client Concentration: Review the reduction in top 10 client concentration for Nurse Travel (down to 48.6% in Q2 2006) and monitor for any loss of major clients.
  • Capital Allocation: Monitor the execution of the $3.5M-$4.0M IT capital expenditure plan and its impact on consultant productivity.
  • Tax Position: Confirm the timeline for the potential reversal of the valuation allowance on deferred tax assets as profitability sustains.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.